These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15678150)

  • 1. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
    Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
    Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
    Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
    Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
    Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
    Mol Ther; 2008 Mar; 16(3):607-17. PubMed ID: 18180774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Shore ND; Morrow MP; McMullan T; Kraynyak KA; Sylvester A; Bhatt K; Cheung J; Boyer JD; Liu L; Sacchetta B; Rosencranz S; Heath EI; Nordquist L; Cheng HH; Tagawa ST; Appleman LJ; Tutrone R; Garcia JA; Whang YE; Kelly WK; Weiner DB; Bagarazzi ML; Skolnik JM
    Mol Ther; 2020 May; 28(5):1238-1250. PubMed ID: 32208168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
    Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
    Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene.
    Fujii R; Iwahashi M; Kikkawa K; Inagaki T; Kohjimoto Y; Ojima T; Mori T; Kuramoto T; Nishizawa S; Azuma I; Yamaue H; Shinka T; Hara I
    BJU Int; 2009 Dec; 104(11):1766-73. PubMed ID: 20063450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.
    Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL
    Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.